Patients with oligometastatic prostate cancer can be identified using highly advanced detection tools, such as positron emission tomography (PET) and full body magnetic resonance imaging (MRI). The question is, what is the next step? Should these patients be kept under observation or should they be offered treatment? Is there a benefit to protocol-based treatment or should treatment be within a clinical trial? In this interesting interview, Adam Dicker, MD, PhD, FASTRO, of Thomas Jefferson University, Philadelphia, PA, provides an insight into the arguments raised for both sides in a case-based debate on this topic at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA.